Mucosal Vaccines, Adjuvants & Delivery
Sep 14, 2016
Aug 15, 2016
9:00 am - 6:00 pm
University of Lausanne, Lausanne, Switzerland
CHUV/University of Lausanne, Lausanne, Switzerland (in collaboration with several ADITEC partners)
Most pathogens access the body through the mucosal membranes. Therefore, effective vaccines that protect at these sites are an important requirement. However, despite early success with the live attenuated oral polio vaccine over 50 years ago, only a few new mucosal vaccines have been subsequently launched. This is partly due to problems with developing safe and effective mucosal adjuvants. In the past decade, however, the successful development of live attenuated mucosal vaccines against influenza virus and rotavirus infections has boosted interest in this field, and the outlook for new mucosal vaccines looks to hold some promise.
There is therefore a major requirement to develop vaccines against many of the pathogens that infect mucosal tissues or have a mucosal port of entry. Parenteral vaccination may protect in some instances, but usually a mucosal vaccination route is necessary. Mucosal vaccines also have logistic advantages over injectable vaccines by being simpler to administer, having less risk of transmitting infections and potentially being easier to manufacture. Still, however, only relatively few vaccines for human use are available: oral vaccines against cholera, typhoid, polio, and rotavirus, and a nasal vaccine against influenza. For polio, typhoid and influenza, in which the pathogens reach the blood stream, there is also an injectable vaccine alternative. A problem with available oral live vaccines is their reduced immunogenicity when used in developing countries; for instance, the efficacy of rotavirus vaccines correlates closely with the national per capita income. Research is required to define the impact of factors such as malnutrition, aberrant intestinal microflora, concomitant infections, and pre-existing immunity as well as of host genetic factors on the immunogenicity of these vaccines.
MUCOVAD 2016 will be an opportunity for researchers to hear updates on new developments in the area of mucosal vaccines and associated adjuvantation and delivery mechanisms/platforms.
MUCOVAD 2016 will be of interest to researchers/contributors from academic programmes, industrial, governmental and regulatory groups.
Advisory Scientific Panel
Conference Chairman: Ted M. Ross (University of Georgia, Athens, Georgia, USA)
John Clements (Tulane University, New Orleans, Louisiana, USA)
Jan Holmgren (Gothenburg University, Gothenburg, Sweden)
Edward Lavelle (Trinity College Dublin, Dublin, Ireland)
Eric Cox (University of Ghent, Ghent, Belgium)
Ali Harandi (Gothenburg University, Gothenburg, Sweden)
Dexiang Chen (PATH, Seattle, Washington, USA)
Rob Lambkin-Williams (hVIVO, London, UK)
Dennis Christensen (Statens Serum Institut, Copenhagen, Denmark)
Richard Walker (PATH, Washington DC, USA)
Anna-Karin Maltais (Eurocine Vaccines AB, Solna, Sweden)
Niranjan Sardesai (INOVIO Inc., Plymouth Meeting, Pennsylvania, USA)
- Developmental aspects of mucosal environment and immunity
- Lessons learned from earlier and existing (available) mucosal vaccines
- Approaches to the development of modern mucosal vaccines/adjuvants and delivery systems
- Considerations of the routes of immunization (sublingual, oral, nasal, rectal, vaginal, intrapulmonary, ocular), antigens and genomics (different challenges at different mucosal sites)
- Developmental aspects of human and veterinary mucosal vaccines/adjuvants currently in progress
- Live vector vaccines/ Particle-based vaccines(including VLPs) /Conjugate vaccines
- Delivery systems and formats – new and future developments (conjugates/particles, liquids/sprays/dry powder/tablet/capsules/enteric coatings)
- Regulatory and Safety requirements for mucosal vaccines/adjuvants